Cargando…
Rac Inhibition Reverses the Phenotype of Fibrotic Fibroblasts
BACKGROUND: Fibrosis, the excessive deposition of scar tissue by fibroblasts, is one of the largest groups of diseases for which there is no therapy. Fibroblasts from lesional areas of scleroderma patients possess elevated abilities to contract matrix and produce α−smooth muscle actin (α-SMA), type...
Autores principales: | Shi-wen, Xu, Liu, Shangxi, Eastwood, Mark, Sonnylal, Sonali, Denton, Christopher P., Abraham, David J., Leask, Andrew |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757676/ https://www.ncbi.nlm.nih.gov/pubmed/19823586 http://dx.doi.org/10.1371/journal.pone.0007438 |
Ejemplares similares
-
Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2
por: Leask, Andrew
Publicado: (2009) -
CCN2 modulates hair follicle cycling in mice
por: Liu, Shangxi, et al.
Publicado: (2013) -
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment
por: Leask, Andrew
Publicado: (2010) -
Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism
por: Chen, Yunliang, et al.
Publicado: (2011) -
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism
por: Chen, Yunliang, et al.
Publicado: (2015)